SCHEDULE: Point72 Discloses 0.3% Stake in Regulus Therapeutics
Beneficial Ownership Disclosure
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen collectively reported a 0.3% beneficial ownership stake in Regulus Therapeutics Inc., primarily through warrants.
Summary
- Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen collectively reported beneficial ownership of 241,157 shares of Regulus Therapeutics Inc. common stock as of June 30, 2025.
- This ownership represents 0.3% of the total class of securities outstanding.
- The reported shares include 241,157 shares issuable upon the exercise of warrants.
- The beneficial ownership calculation is based on 69,475,246 shares outstanding, which includes 69,234,089 shares reported as of May 2, 2025, plus the 241,157 warrant shares.
- The reporting persons hold shared voting power and shared dispositive power over all 241,157 shares, with no sole voting or dispositive power.
- The filing is a Schedule 13G, indicating a passive investment purpose, not for changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a factual ownership disclosure with no inherent positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future operations or financial performance.
Industry Context
This filing is a routine disclosure of passive investment ownership by a major investment firm in a biotechnology company. It does not provide specific insights into broader industry trends or competitive dynamics beyond the fact of the investment itself.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant passive ownership by institutional investors, which can be a signal of investor interest, though the percentage is small.
Key Dates
| Date | Description |
|---|---|
| 2025-05-02 | Date of shares outstanding reported in Issuer's Form 10-Q. |
| 2025-06-30 | Date of event which requires filing of this statement (beneficial ownership as of this date). |
| 2025-08-14 | Date of filing of this statement. |
Keywords
Regulus Therapeutics, Point72 Asset Management, Steven A. Cohen, Beneficial Ownership, Schedule 13G, Warrants, Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.